Avita Medical Ltd (RCEL)
Avita Medical Ltd is a healthcare company focused on therapeutic acute wound care. The company develops and commercializes the RECELL System, a cell-harvesting device used in the treatment of thermal burn wounds and full-thickness skin defects, and for repigmenting stable depigmented vitiligo lesions. Its product range also includes the RECALL autologous cell harvesting device, RECELL autologous cell harvesting devices designed for easier use, and the RECELL GO line for smaller wound areas. In addition, Avita Medical sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. The company serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, it was formerly known as AVITA Therapeutics, Inc. before adopting its current name in December 2020.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RCEL
|
$5.25
|
0.3% Upside
|
Fair
|
$9.10
|
73.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-3.6x
|
-7.0x
|
2.2x
|
158.2 M
|
195.5 M
|
23.3%
|
98.4%
|
-13.6
|
—
|
70.1%
|